season
influenza
viru
infect
caus
signific
morbid
mortal
lead
estim
death
worldwid
death
unit
state
major
antigen
shift
associ
genet
reassort
led
devast
pandem
pathogen
virus
effici
humantohuman
transmiss
enter
human
popul
preexist
avian
influenza
viru
recent
emerg
influenza
pandem
viru
swine
origin
pose
seriou
threat
human
health
recent
data
mammalian
transmiss
experiment
underscor
continu
pandem
threat
pose
major
influenza
infect
subclin
control
innat
adapt
immun
respons
sever
diseas
associ
direct
virusmedi
cytopath
effect
alveolar
epithelium
result
excess
dysregul
immun
respons
lead
extens
lung
inflamm
direct
correl
viral
titer
local
system
cytokin
respons
symptom
patient
suffer
mild
season
influenza
suggest
host
innat
immun
respons
contribut
clinic
symptom
mild
inflammatori
cell
infiltr
pulmonari
tissu
togeth
direct
virusmedi
cytopath
effect
creat
airway
congest
impair
ga
exchang
precipit
acut
respiratori
distress
experiment
influenza
viru
infect
human
confirm
find
show
increas
concentr
sever
inflammatori
mediat
includ
interleukin
il
tumornecrosi
nasopharyng
lavag
fluid
volunt
infect
patient
sever
fatal
human
infect
viru
higher
proinflammatori
respons
earli
ill
although
viral
load
nasopharynx
appear
sever
fatal
diseas
human
associ
higher
viral
load
well
enhanc
proinflammatori
respons
pathogen
virus
avian
intrins
capac
elicit
enhanc
innat
immun
respons
primari
human
macrophag
alveolar
epitheli
cell
role
inflammatori
respons
pathogenesi
sever
lung
diseas
macaqu
infect
avian
influenza
virus
although
mice
defect
individu
cytokin
chemokin
pathway
steroidtr
wildtyp
mice
surviv
advantag
wildtyp
mice
viral
mice
lack
tumornecrosi
factor
receptor
reduc
morbid
delay
proofofconcept
develop
antiinflammatori
drug
treatment
infecti
diseas
recent
present
context
influenza
dengu
polymicrobi
increas
attent
role
immunomodulatori
intervent
adjunct
therapi
outcom
influenza
viru
infect
determin
viral
host
factor
mani
studi
investig
efficaci
therapeut
strategi
target
host
combin
convent
antivir
approv
immunomodulatori
drug
clinic
use
molecul
particularli
attract
approach
due
known
safeti
profil
current
standardofcar
drug
influenza
viru
infect
includ
neuraminidas
inhibitor
oseltamivir
zanamivir
inhibit
viral
replic
direct
effect
underli
inflamm
although
antivir
therapi
improv
clinic
outcom
patient
zoonot
viru
diseas
even
earli
first
day
ill
oseltamivir
treatment
address
unaccept
mortal
novel
drug
attenu
sever
downmodul
inflammatori
respons
use
conjunct
neuraminidas
inhibitor
would
constitut
signific
improv
therapeut
armamentarium
season
pandem
influenza
earli
attempt
use
antiinflammatori
dose
control
excess
inflamm
sever
acut
respiratori
infect
like
sever
acut
respiratori
syndrom
coronaviru
associ
sever
side
effect
without
improv
patient
treat
moder
dose
statin
reduc
risk
death
influenza
suggest
decreas
inflammatori
respons
may
account
protect
sever
howev
studi
limit
carri
retrospect
without
placebo
control
combin
neuraminidas
inhibitor
zanamivir
antiinflammatori
compound
celecoxib
mesalazin
increas
surviv
mice
infect
highli
pathogen
strain
influenza
select
serotonin
reuptak
inhibitor
ssri
inhibitor
shown
exert
immunomodulatori
activ
vivo
particular
pde
inhibitor
rolipram
sertralin
proven
antiinflammatoryimmunomodulatori
properti
preclin
clinic
effect
influenza
viru
infect
unknown
demonstr
combin
approv
oral
avail
immunomodulatori
drug
oseltamivir
significantli
reduc
mortal
experiment
influenza
infect
mice
propos
approv
clinic
stage
immunomodul
combin
standard
care
neuraminidas
inhibitor
consid
preclin
develop
current
circul
strain
male
mice
weigh
g
procur
biolog
resourc
centr
singapor
hous
group
five
cage
corncob
bed
experi
conduct
anim
biosafeti
level
room
cage
place
isol
maintain
pa
pressur
suppli
higheffici
particul
airfilt
air
mice
provid
commerci
rodent
diet
harlanteklad
bicest
uk
drink
water
ad
libitum
anim
handl
strict
accord
good
anim
practic
anim
work
approv
institut
anim
care
use
committe
biolog
resourc
centr
institut
anim
care
use
committe
influenza
viru
obtain
american
type
cultur
collect
titer
tissu
cultur
infecti
dose
viru
amplifi
canin
kidney
mdck
cell
maintain
minim
essenti
medium
bovin
serum
albumin
presenc
l
ethyl
chloromethyl
ketonetr
trypsin
sigmaaldrich
singapor
mdck
cell
line
obtain
american
type
cultur
collect
maintain
minim
essenti
medium
supplement
fetal
bovin
serum
penicillin
streptomycin
rolipram
oseltamivir
obtain
kemprotec
ltd
middlesbrough
uk
sertralin
obtain
atomax
chemic
co
ltd
shenzen
china
enzymelink
immunosorb
assay
reagent
r
system
minneapoli
usa
minimum
essenti
medium
bovin
serum
albumin
obtain
gibco
life
technolog
singapor
l
ethyl
chloromethyl
ketonetr
trypsin
penicillin
streptomycin
sigma
vitro
antivir
activ
singl
agent
combin
determin
use
cellbas
antivir
assay
monitor
inhibit
cytopath
effect
cpe
mdck
cell
induc
influenza
viru
presenc
absenc
antivir
activ
express
percentag
viru
inhibit
one
half
dilut
test
compound
ad
cell
min
prior
viru
infect
remain
entir
durat
assay
h
util
inoculum
cell
cultur
infecti
dose
per
well
seed
mdck
cell
form
monolay
microtit
plate
cytotox
control
uninfect
cell
includ
concentr
test
compound
control
includ
uninfect
control
uninfect
cell
test
medium
viru
control
cell
viru
drug
diluent
antivir
activ
express
half
maxim
inhibitori
concentr
determin
regress
analysi
cpe
inhibit
data
intranas
viral
inocul
male
mice
carri
anesthesia
ketamin
mgkg
xylazin
mgkg
viru
stock
dilut
phosphatebuff
salin
work
concentr
viru
administ
intranas
mous
viral
titer
select
base
preliminari
observ
result
mortal
mice
day
data
shown
drug
administ
oral
twice
daili
day
start
h
infect
prophylact
set
h
postinfect
therapeut
set
dose
oseltamivir
use
mgkgday
two
divid
dose
per
day
basi
equival
human
dose
base
exposur
activ
metabolit
rolipram
sertralin
administ
mgkg
equival
human
dose
sertralin
rolipram
formul
suspens
hydroxi
propyl
methyl
cellulos
sigmaaldrich
singapor
oseltamivir
dissolv
distil
water
surviv
studi
mice
group
weigh
daili
weight
use
dose
adjust
surviv
bodi
weight
anim
monitor
day
cytokin
determin
cell
recruit
broncheoalveolar
lavag
fluid
balf
collect
kill
six
mice
group
day
postinfect
trachea
catheter
tube
normal
salin
infus
collect
balf
total
number
cell
balf
count
use
hemocytomet
balf
supernat
store
aliquot
kept
frozen
quantifi
cytokin
per
protocol
r
system
histopatholog
evalu
mice
group
sacrif
day
lung
sampl
collect
neutralbuff
formalin
hematoxylin
eosin
stain
tissu
section
tissu
section
observ
rel
degre
inflammatori
lesion
day
viru
infect
group
six
mice
kill
treatment
control
group
lung
immedi
snap
frozen
follow
storag
lung
homogen
wv
suspens
minimum
essenti
medium
contain
centrifug
g
min
variou
dilut
supernat
sampl
assay
triplic
infecti
viru
titer
mdck
cell
seed
flatbottom
micropl
viral
cytopath
effect
determin
visual
end
point
describ
viru
titer
report
lung
tissu
surviv
time
rate
perform
logrank
test
individu
treatment
pairwis
compar
vehicl
control
group
signific
level
report
p
p
p
similarli
individu
treatment
group
pairwis
compar
oseltamivir
treat
group
signific
level
report
p
p
p
statist
analysi
mean
day
death
viru
titer
lung
homogen
biomark
cell
recruit
cytokin
perform
use
oneway
analysi
varianc
follow
post
hoc
test
signific
p
valu
treatment
group
compar
control
report
signific
p
valu
treatment
group
compar
oseltamivir
treat
group
report
oseltamivir
sertralin
rolipram
evalu
antivir
activ
influenza
cytopath
assay
use
mdck
cell
oseltamivir
determin
figur
eight
differ
concentr
oseltamivir
rang
combin
differ
concentr
sertralin
rolipram
drug
use
concentr
cytotox
demonstr
cell
viabil
assay
neither
sertralin
rolipram
found
antivir
activ
singl
agent
figur
tabl
show
potenc
oseltamivir
increas
presenc
either
sertralin
rolipram
data
repres
fold
chang
oseltamivir
sertralin
rolipram
compar
oseltamivir
alon
statist
signific
fold
chang
calcul
extra
sum
squar
f
test
p
consid
viral
replic
inhibit
observ
combin
significantli
superior
oseltamivir
alon
emerg
experi
increas
surviv
combin
group
observ
earlier
experi
due
enhanc
antivir
activ
combin
evalu
abil
sertralin
rolipram
reduc
mortal
increas
surviv
time
influenza
virusinfect
mice
administ
singl
agent
combin
oseltamivir
prophylact
set
treatment
initi
h
preinfect
drug
administr
continu
day
twice
daili
oseltamivir
dose
use
studi
mgkgday
equival
human
dose
base
activ
metabolit
exposur
mice
vehicletr
group
start
die
day
day
anim
succumb
infect
overal
surviv
oseltamivir
group
day
increas
mean
day
death
observ
compar
control
sertralin
demonstr
signific
effect
mortal
surviv
time
use
alon
howev
oseltamivir
sertralin
combin
group
surviv
rate
day
p
compar
oseltamivir
group
test
figur
although
signific
differ
bodi
weight
observ
group
figur
signific
increas
mean
day
death
observ
combin
group
compar
oseltamivir
alon
test
p
figur
rolipram
singl
agent
result
surviv
day
surviv
oseltamivir
combin
group
p
compar
oseltamivir
alon
test
increas
mean
day
death
p
combin
group
compar
oseltamivir
alon
figur
therapeut
set
treatment
initi
h
postinfect
surviv
rolipramoseltamivir
group
compar
rolipram
oseltamivir
singl
agent
group
figur
signific
differ
bodi
weight
observ
group
figur
although
increas
mean
day
death
statist
signific
surviv
observ
day
group
treat
sertralin
alon
combin
group
surviv
thu
signific
increas
surviv
observ
combin
group
compar
oseltamivir
alon
combin
oseltamivir
rolipram
effect
prevent
mortal
compar
sertralin
chang
mean
day
death
combin
group
sertralin
oseltamivir
figur
explor
mechan
action
combin
drug
studi
evalu
vivo
antivir
activ
inflammatori
biomark
lung
histopatholog
mice
treat
oseltamivir
sertralin
rolipram
singl
agent
combin
h
infect
influenza
viru
treatment
continu
day
lung
sampl
harvest
day
antivir
efficaci
drug
administr
determin
titrat
infecti
viru
load
lung
homogen
cell
culturebas
assay
sertralin
rolipram
singl
agent
demonstr
antivir
effect
oseltamivir
alon
show
signific
decreas
lung
viral
titer
p
combin
p
tabl
howev
effect
combin
significantli
differ
oseltamivir
alon
conclud
antivir
effect
seen
combin
group
due
oseltamivir
compon
clear
vitro
vivo
antivir
efficaci
studi
sertralin
rolipram
alon
antivir
effect
combin
better
oseltamivir
alon
correl
inflamm
mortal
infect
mice
inflammatori
biomark
quantifi
balf
mice
treat
oseltamivir
sertralin
rolipram
combin
day
postinfect
signific
decreas
cell
recruit
balf
figur
treat
group
compar
vehicletr
group
p
howev
compar
mice
treat
oseltamivir
alon
signific
decreas
cellular
recruit
combin
group
well
rolipram
singleag
group
p
level
proinflammatori
cytokin
chemokin
regul
activ
normal
cell
express
secret
monocyt
chemotact
significantli
reduc
balf
anim
combin
group
compar
oseltamivir
group
p
p
figur
histolog
influenza
virusinfect
anim
show
lesion
typic
influenza
viru
infect
inflammatori
chang
bronchiol
peribronchi
area
exud
bronchiol
caviti
alveoli
histolyt
alveol
lung
consolid
prophylact
intervent
demonstr
fewer
inflammatori
chang
viru
group
howev
combin
treatment
group
day
show
fewer
inflammatori
chang
bronchiol
peribronchi
area
alveolar
region
compar
singl
agent
viru
control
group
figur
clinic
use
approv
drug
advantag
develop
differ
indic
due
known
sideeffect
profil
bioavail
interact
potenti
investig
antiinflammatori
drug
rolipram
inhibitor
sertralin
ssri
alon
combin
oseltamivir
show
rolipram
alon
well
rolipram
sertralin
combin
oseltamivir
increas
surviv
delay
reduc
mortal
reduc
lung
inflamm
influenza
viru
experiment
mous
model
sertralin
belong
ssri
class
drug
antidepress
routin
use
immunomodulatori
effect
howev
shown
immunomodulatori
antiinflammatori
proinflammatori
cytokin
process
specif
regul
tumornecrosi
addit
suppress
helper
immunomodulatori
effect
ssri
sertralin
paroxetin
human
lymphocyt
function
gene
express
tremain
et
demonstr
sertralin
level
lung
almost
time
target
organ
brain
although
sertralin
use
gener
proofofconcept
improv
efficaci
mice
could
reluct
part
patient
physician
use
central
nervou
system
drug
respiratori
infect
led
us
explor
noncentr
nervou
system
antiinflammatori
drug
rolipram
inhibitor
inhibitor
current
develop
treatment
respiratori
diseas
includ
asthma
chronic
obstruct
pulmonari
rational
develop
drug
class
stem
understand
role
suppress
function
rang
inflammatori
resid
cell
thought
contribut
pathogenesi
diseas
pde
famili
enzym
respons
metabol
intracellular
second
messeng
cyclic
adenosin
monophosph
camp
cyclic
guanosin
monophosph
campspecif
pde
major
sole
campmetabol
enzym
found
inflammatori
immun
cell
contribut
significantli
camp
metabol
smooth
muscl
base
cellular
tissu
distribut
demonstr
select
inhibitor
isozym
reduc
bronchoconstrict
anim
suppress
activ
inflammatori
cell
becom
import
molecular
target
develop
novel
therapi
asthma
chronic
obstruct
pulmonari
diseas
numer
preclin
vivo
studi
shown
inhibitor
suppress
characterist
featur
diseas
name
cell
recruit
activ
inflammatori
cell
physiolog
chang
lung
function
respons
rang
airway
insult
potenti
benefici
action
inhibitor
success
translat
clinic
trial
roflumilast
cilomilast
chronic
obstruct
pulmonari
inhibitor
develop
airway
diseas
therefor
drug
select
achiev
high
lung
level
desir
pharmacolog
properti
therapeut
intend
use
respiratori
infect
signific
decreas
inflammatori
biomark
also
observ
agreement
mechan
action
compound
rolipram
also
demonstr
attenu
respiratori
syncyti
virusinduc
airway
hyperrespons
lung
data
show
antiinflammatori
drug
belong
ssri
class
improv
morbid
mortal
sever
influenza
mous
model
use
combin
antivir
drug
oseltamivir
rolipramoseltamivir
combin
achiev
protect
treat
anim
prophylact
set
therapeut
set
signific
surviv
rate
could
still
achiev
rolipram
alon
underscor
superior
inhibitor
sertralin
neither
two
antiinflammatori
drug
demonstr
direct
antivir
activ
vitro
vivo
demonstr
cpe
assay
lung
viral
load
measur
respect
oseltamivir
dose
mgkg
equival
human
dose
base
activ
metabolit
exposur
reduc
lung
viral
load
oseltamivirdepend
lung
viral
titer
reduct
experiment
anim
vari
significantli
accord
viru
strain
oseltamivir
dose
anim
model
mous
model
use
lung
viral
load
reduct
seen
studi
consist
previou
data
sidwel
demonstr
benefici
effect
surviv
lung
patholog
observ
combin
group
attribut
reduct
inflammatori
respons
signific
decreas
inflammatori
biomark
compar
oseltamivir
alon
correl
posit
reduc
lung
inflammatori
lesion
mortal
increas
surviv
time
seen
mice
treat
rolipram
sertralin
combin
oseltamivir
basi
avail
literatur
metabol
pathway
util
oseltamivir
antiinflammatori
drug
use
studi
likelihood
pharmacokineticbas
drug
interact
drug
use
combin
low
drug
interact
result
increas
concentr
either
drug
inhibit
metabol
pathway
thu
lead
alter
pharmacodynam
toxic
outcom
drug
use
combin
studi
metabol
total
distinct
pathway
oseltamivir
extens
convert
activ
metabolit
esteras
present
liver
wherea
antiinflammatori
drug
rolipram
sertralin
shown
undergo
phase
metabol
util
cytochrom
neither
oseltamivir
activ
metabolit
substrat
inhibitor
major
cytochrom
isoform
thu
interact
mediat
competit
enzym
unlik
rule
essenti
problem
interact
find
present
provid
new
experiment
evid
therapeut
option
use
antiinflammatori
drug
use
adjunct
antivir
improv
diseas
outcom
random
control
clinic
trial
patient
influenza
need
evalu
treatment
strategi
immunomodulatori
agent
